AI helps scientists design the next generation of medicines (www.technologyreview.com)

AstraZeneca is utilizing artificial intelligence (AI) to revolutionize the design and development of biologic medicines, which traditionally face extensive timelines and high failure rates. By integrating AI into the drug discovery process, AstraZeneca aims to streamline the identification of viable drug candidates, enabling scientists to focus on the most promising molecules generated through AI's predictive capabilities. This approach not only accelerates timelines but also enhances productivity in the research and development stage, allowing for the exploration of disease targets previously deemed untreatable. The AI-assisted design process follows a cyclical model of building, measuring, and learning, facilitating a tighter feedback loop that significantly reduces dead ends in drug design. The significance of this advancement lies in its potential to expedite the development of multi-specific biologics that can target multiple disease pathways, thereby optimizing treatment outcomes. AstraZeneca is also constructing a "lab of the future" that combines AI with robotic automation to create a continuous discovery system, generating vast amounts of AI-ready data. This system is expected to support the ambitious goal of "de novo" design, where AI generates entirely new protein sequences tailored to specific therapeutic needs. By combining cutting-edge AI with robust human oversight, AstraZeneca is poised to advance the field of drug development, potentially enabling innovations that could transform patient care.